Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma

Launched by UNIVERSITY HOSPITAL, GENEVA · Nov 30, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a specific treatment called stereotactic radiosurgery (SRS) affects people with a type of tumor known as vestibular schwannoma, which can impact hearing and balance. The researchers want to see how this treatment influences not only hearing and balance but also other nerve functions, like taste and facial movement. They will compare the results of patients who received SRS with those who chose to monitor their condition without immediate treatment. Additionally, participants will fill out questionnaires about their quality of life to help understand the broader impact of these treatments.

To be eligible for this study, participants need to be at least 18 years old and have a unilateral vestibular schwannoma, meaning the tumor is on one side. They should be willing to participate and provide their consent. However, those who have had prior surgery or radiation for the tumor, those with certain genetic conditions, or those with significant pre-existing hearing loss are not eligible. If you join the study, you can expect to be closely monitored and to contribute your experiences, helping to improve understanding of this condition and its treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 years or above
• • Patients with unilateral VS treated either with SRS or MRI-based observation strategy, as proposed by the institution's skull base tumor board independently of the study
• • Patients willing to take part in the study and give their informed consent
• Exclusion Criteria:
• • Previous surgical or radiation therapy for VS (including SRS)
• • Patients diagnosed with neurofibromatosis type II
• • Preexisting profound hearing loss, with a pure tone average (PTA) \>90 and word recognition score (WRS) \<10%, upon initial assessment
• • Previous middle ear surgery of the affected ear
• • Concurrent treatment with other experimental drugs